View on PubMed Retatrutide in Type 2 Diabetes with Inadequate Glycaemic Control: Phase 3 Trial (TRANSCEND-T2D-1) Phase 3 double-blind RCT confirming retatrutide produces significant HbA1c reduction and body weight loss in adults with type 2 diabetes, establishing its dual metabolic benefit across glycaemic control and body composition in a large clinical trial (Lancet, 2026)
29,54 The STEP-HFpEF trial reported a reduction in systolic BP by an average of 4.9 mmHg in the semaglutide group, compared to a reduction of 2.0 mmHg in the placebo group, in a mean difference of 2.9 mmHg
10.1002/dta.30 20 GrantB.CampbellJ.PradeepA.BurnsA
Exercise is a great tool to help you keep the weight off
In spite of their limitations, these studies are the first to demonstrate a capacity of exogenously administered NAC to reach the CNS
That means your injection may no longer provide the same metabolic or appetite-suppressing effect, even if it looks normal